Meeting
2018 ASCO Annual Meeting
Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.
Authors
Cathy Yi Xia
Melanoma Institute Australia, Sydney, Australia
Cathy Yi Xia , Daniel Ying Wang , Robert Mason , Jessica Louise Smith , Meredith Ann McKean , Serigne Lo , Alexander David Guminski , Georgina V. Long , Matteo S. Carlino , Victoria Atkinson , Michael Millward , Jennifer Leigh McQuade , Rodabe Navroze Amaria , Douglas Buckner Johnson , Alexander M. Menzies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9532)
DOI
10.1200/JCO.2018.36.15_suppl.9532
Abstract #
9532
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
First Author: Adriana Matutino Kahn
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Healthcare resource utilization in first-line immunotherapies for patients with metastatic melanoma.
First Author: Frank Xiaoqing Liu
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
First Author: Jason J. Luke
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.
First Author: Sameer Ghate